Cyclacel Pharmaceuticals, Inc. (CYCC) Tops Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. GOOGL
6. APLD
7. ORCL
8. USO
9. STZ
10. AAPL

Go back to Cyclacel Pharmaceuticals, Inc. (CYCC) Tops Q2 EPS by 8c

Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results

August 12, 2014 4:05 PM EDT

BERKELEY HEIGHTS, N.J., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter ended June 30, 2014.

The Company's net loss applicable to common shareholders for the second quarter ended June 30, 2014 was $4.9 million, or $0.22 per basic and diluted share, compared to net income applicable to common shareholders of... More